Vistagen Therapeutics (VTGN) Cash from Operations (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Cash from Operations of 16200000.0 for Q1 2026, up 7.93% sequentially from 17595000.0 in Q4 2025, and down 61.0% YoY from 41540366.97 in Q1 2025.
Vistagen Therapeutics (VTGN) Cash from Operations (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Cash from Operations for 17 years, with the latest figure at 16200000.0 in Q1 2026.
- Quarterly Cash from Operations fell 61.0% year-over-year to 16200000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66400000.0 (down 57.73% YoY) and the FY2026 annual result came in at 66400000.0, down 57.73% from the prior year.
- Cash from Operations climbed to 16200000.0 in Q1 2026 per VTGN's latest filing, from 17595000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 4747000.0 in Q4 2023 and troughed at 18800000.0 in Q2 2025.
- A 5-year average of 11742029.41 and a median of 10869000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 195.13% in 2022, then soared 62.12% in 2023.
- Over 5 years, Cash from Operations stood at 9933300.0 in 2022, then jumped by 52.21% to 4747000.0 in 2023, then plunged by 116.56% to 10280000.0 in 2024, then slumped by 71.16% to 17595000.0 in 2025, then gained by 7.93% to 16200000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 16200000.0, 17595000.0, and 13805000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | -14.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.20 Mn |
| Mar 31, 2026 | -16.20 Mn |
| Dec 31, 2025 | -17.60 Mn |
| Dec 31, 2025 | -17.60 Mn |
| Sep 30, 2025 | -13.81 Mn |
| Sep 30, 2025 | -13.81 Mn |
| Jun 30, 2025 | -18.80 Mn |
| Jun 30, 2025 | -18.80 Mn |
| Mar 31, 2025 | -10.06 Mn |
| Mar 31, 2025 | -10.06 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Dec 31, 2024 | -10.28 Mn |
| Sep 30, 2024 | -10.89 Mn |
| Sep 30, 2024 | -10.89 Mn |
| Jun 30, 2024 | -10.87 Mn |
| Jun 30, 2024 | -10.87 Mn |
| Mar 31, 2024 | -6.99 Mn |
| Mar 31, 2024 | -6.99 Mn |
| Dec 31, 2023 | -4.75 Mn |
| Dec 31, 2023 | -4.75 Mn |